Handelen Kymera Therapeutics, Inc. - KYMR CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.08 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Prev. Close* | 28.81 |
Open* | 28.23 |
1-Jaarlijkse Verandering* | -30.93% |
Dagelijks bereik* | 28.23 - 29.53 |
52 wekelijks bereik | 13.15-44.75 |
Weekgemiddelde volume (10 dagen) | 429.92K |
Gemiddeld volume (3 maanden) | 10.82M |
Marktkapitalisatie | 1.59B |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 55.18M |
Omzet | 46.83M |
EPS | -2.88 |
Dividend (opbrengst %) | N/A |
Beta | -100.00K |
Volgende inkomsten datum | May 1, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 29.30 | 0.88 | 3.10% | 28.42 | 29.57 | 28.03 |
Mar 23, 2023 | 28.81 | 0.33 | 1.16% | 28.48 | 29.50 | 27.81 |
Mar 22, 2023 | 28.05 | -1.67 | -5.62% | 29.72 | 30.03 | 28.03 |
Mar 21, 2023 | 30.00 | -0.08 | -0.27% | 30.08 | 31.03 | 29.91 |
Mar 20, 2023 | 30.71 | 0.74 | 2.47% | 29.97 | 31.00 | 29.76 |
Mar 17, 2023 | 30.98 | 0.89 | 2.96% | 30.09 | 31.25 | 29.60 |
Mar 16, 2023 | 31.01 | 0.35 | 1.14% | 30.66 | 31.59 | 29.77 |
Mar 15, 2023 | 31.10 | 0.26 | 0.84% | 30.84 | 31.52 | 29.93 |
Mar 14, 2023 | 31.57 | -0.59 | -1.83% | 32.16 | 33.08 | 30.85 |
Mar 13, 2023 | 31.15 | 2.50 | 8.73% | 28.65 | 31.37 | 28.65 |
Mar 10, 2023 | 29.56 | -1.41 | -4.55% | 30.97 | 31.26 | 28.44 |
Mar 9, 2023 | 31.66 | -0.36 | -1.12% | 32.02 | 33.39 | 31.30 |
Mar 8, 2023 | 33.10 | 1.08 | 3.37% | 32.02 | 33.15 | 32.02 |
Mar 7, 2023 | 32.85 | 0.33 | 1.01% | 32.52 | 33.66 | 32.11 |
Mar 6, 2023 | 32.58 | 0.11 | 0.34% | 32.47 | 32.85 | 31.47 |
Mar 3, 2023 | 32.76 | 0.21 | 0.65% | 32.55 | 32.90 | 31.88 |
Mar 2, 2023 | 32.41 | 0.77 | 2.43% | 31.64 | 32.69 | 30.12 |
Mar 1, 2023 | 32.04 | 0.62 | 1.97% | 31.42 | 32.12 | 30.83 |
Feb 28, 2023 | 31.37 | -0.48 | -1.51% | 31.85 | 33.04 | 31.03 |
Feb 27, 2023 | 31.90 | -0.03 | -0.09% | 31.93 | 32.39 | 30.94 |
Kymera Therapeutics, Inc. Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Totale inkomsten | 72.832 | 34.034 | 2.934 | 0 |
Inkomsten | 72.832 | 34.034 | 2.934 | 0 |
Totale bedrijfskosten | 173.362 | 80.338 | 45.139 | 21.451 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 36.345 | 18.233 | 7.981 | 3.772 |
Onderzoek & Ontwikkeling | 137.017 | 62.105 | 37.158 | 17.679 |
Bedrijfsresultaat | -100.53 | -46.304 | -42.205 | -21.451 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.313 | 0.711 | 0.959 | -0.016 |
Netto inkomen voor belastingen | -100.217 | -45.593 | -41.246 | -21.467 |
Netto inkomen na belastingen | -100.217 | -45.593 | -41.246 | -21.467 |
Netto inkomen voor extra. Posten | -100.217 | -45.593 | -41.246 | -21.467 |
Netto inkomen | -100.217 | -45.593 | -41.246 | -21.467 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -100.217 | -54.643 | -41.246 | -21.467 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -100.217 | -54.643 | -41.246 | -21.467 |
Verwaterd Netto Inkomen | -100.217 | -54.643 | -41.246 | -21.467 |
Verwaterd Gewogen Gemiddelde Aandelen | 47.989 | 44.4822 | 43.1386 | 43.1386 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.08833 | -1.22842 | -0.95613 | -0.49763 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -2.08833 | -1.22842 | -0.95613 | -0.49763 |
Total Adjustments to Net Income | 0 | -9.05 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale inkomsten | 9.622 | 15.275 | 20.336 | 18.519 | 18.702 |
Inkomsten | 9.622 | 15.275 | 20.336 | 18.519 | 18.702 |
Totale bedrijfskosten | 46.555 | 49.269 | 48.973 | 43.249 | 31.871 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 10.611 | 11.74 | 10.667 | 8.029 | 5.909 |
Onderzoek & Ontwikkeling | 35.944 | 37.529 | 38.306 | 35.22 | 25.962 |
Bedrijfsresultaat | -36.933 | -33.994 | -28.637 | -24.73 | -13.169 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.249 | 0.094 | 0.055 | 0.07 | 0.094 |
Netto inkomen voor belastingen | -36.684 | -33.9 | -28.582 | -24.66 | -13.075 |
Netto inkomen na belastingen | -36.684 | -33.9 | -28.582 | -24.66 | -13.075 |
Netto inkomen voor extra. Posten | -36.684 | -33.9 | -28.582 | -24.66 | -13.075 |
Netto inkomen | -36.684 | -33.9 | -28.582 | -24.66 | -13.075 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -36.684 | -33.9 | -28.582 | -24.66 | -13.075 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -36.684 | -33.9 | -28.582 | -24.66 | -13.075 |
Verwaterd Netto Inkomen | -36.684 | -33.9 | -28.582 | -24.66 | -13.075 |
Verwaterd Gewogen Gemiddelde Aandelen | 51.6511 | 51.4312 | 50.7149 | 45.0942 | 44.6496 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.71023 | -0.65913 | -0.56358 | -0.54685 | -0.29284 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -0.71023 | -0.65913 | -0.56358 | -0.54685 | -0.29284 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Totaal vlottende activa | 451.273 | 302.339 | 92.845 | 41.79 |
Geldmiddelen en kortetermijnbeleggingen | 442.418 | 296.202 | 91.957 | 41.26 |
Geldmiddelen & Equivalenten | 47.976 | 31.004 | 76.015 | 41.26 |
Korte Termijn Investeringen | 394.442 | 265.198 | 15.942 | 0 |
Totale Vorderingen, Netto | 0.135 | 1.433 | 0 | 0.148 |
Prepaid Expenses | 8.72 | 4.704 | 0.888 | 0.382 |
Total Assets | 605.905 | 487.175 | 116.702 | 44.231 |
Property/Plant/Equipment, Total - Net | 21.307 | 20.686 | 22.083 | 2.242 |
Property/Plant/Equipment, Total - Gross | 25.223 | 22.833 | 23.132 | 2.466 |
Accumulated Depreciation, Total | -3.916 | -2.147 | -1.049 | -0.224 |
Other Long Term Assets, Total | 8.138 | 1.619 | 1.774 | 0.199 |
Total Current Liabilities | 92.542 | 110.617 | 34.57 | 4.687 |
Accounts Payable | 4.005 | 4.368 | 3.276 | 2.056 |
Accrued Expenses | 25.08 | 12.896 | 7.175 | 2.225 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.138 | 0.689 | 0.681 | 0.302 |
Other Current Liabilities, Total | 62.319 | 92.664 | 23.438 | 0.104 |
Total Liabilities | 146.267 | 203.287 | 82.028 | 5.238 |
Total Long Term Debt | 1.14 | 0.604 | 1.165 | 0.393 |
Capital Lease Obligations | 1.14 | 0.604 | 1.165 | 0.393 |
Other Liabilities, Total | 52.585 | 92.066 | 46.293 | 0.158 |
Total Equity | 459.638 | 283.888 | 34.674 | 38.993 |
Redeemable Preferred Stock | 109.08 | 73.429 | ||
Common Stock | 0.005 | 0.004 | 0 | 0 |
Additional Paid-In Capital | 689.275 | 412.777 | 2.044 | 0.774 |
Retained Earnings (Accumulated Deficit) | -228.982 | -128.765 | -76.456 | -35.21 |
Other Equity, Total | -0.66 | -0.128 | 0.006 | 0 |
Total Liabilities & Shareholders’ Equity | 605.905 | 487.175 | 116.702 | 44.231 |
Total Common Shares Outstanding | 51.5362 | 44.4822 | 43.1386 | 43.1386 |
Accounts Receivable - Trade, Net | 0.135 | 0.856 | ||
Long Term Investments | 125.187 | 162.531 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totaal vlottende activa | 431.382 | 451.273 | 543.731 | 364.806 | 340.791 |
Geldmiddelen en kortetermijnbeleggingen | 420.812 | 442.418 | 536.386 | 359.107 | 333.537 |
Geldmiddelen & Equivalenten | 33.733 | 47.976 | 156.819 | 84.903 | 53.098 |
Korte Termijn Investeringen | 387.079 | 394.442 | 379.567 | 274.204 | 280.439 |
Totale Vorderingen, Netto | 1.263 | 0.135 | 1.573 | 0.904 | 1.734 |
Accounts Receivable - Trade, Net | 1.263 | 0.135 | 1.573 | 0.904 | 0.878 |
Prepaid Expenses | 9.307 | 8.72 | 5.772 | 4.795 | 5.52 |
Total Assets | 563.06 | 605.905 | 642.453 | 434.386 | 464.552 |
Property/Plant/Equipment, Total - Net | 21.066 | 21.307 | 21.724 | 21.766 | 20.502 |
Property/Plant/Equipment, Total - Gross | 25.668 | 25.223 | 24.951 | 24.942 | 23.127 |
Accumulated Depreciation, Total | -4.602 | -3.916 | -3.227 | -3.176 | -2.625 |
Long Term Investments | 102.478 | 125.187 | 74.692 | 45.305 | 101.639 |
Other Long Term Assets, Total | 8.134 | 8.138 | 2.306 | 2.509 | 1.62 |
Total Current Liabilities | 88.339 | 92.542 | 94.493 | 108.685 | 110.137 |
Accounts Payable | 2.567 | 4.005 | 5.033 | 8.177 | 8.348 |
Accrued Expenses | 22.913 | 25.08 | 21.105 | 16.838 | 12.962 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.087 | 1.138 | 1.189 | 1.038 | 0.64 |
Other Current Liabilities, Total | 61.772 | 62.319 | 67.166 | 82.632 | 88.187 |
Total Liabilities | 134.34 | 146.267 | 159.318 | 176.282 | 189.305 |
Total Long Term Debt | 0.927 | 1.14 | 1.347 | 1.145 | 0.498 |
Capital Lease Obligations | 0.927 | 1.14 | 1.347 | 1.145 | 0.498 |
Other Liabilities, Total | 45.074 | 52.585 | 63.478 | 66.452 | 78.67 |
Total Equity | 428.72 | 459.638 | 483.135 | 258.104 | 275.247 |
Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.004 |
Additional Paid-In Capital | 697.597 | 689.275 | 678.358 | 424.599 | 417.096 |
Retained Earnings (Accumulated Deficit) | -265.666 | -228.982 | -195.082 | -166.5 | -141.84 |
Other Equity, Total | -3.216 | -0.66 | -0.146 | 0 | -0.013 |
Total Liabilities & Shareholders’ Equity | 563.06 | 605.905 | 642.453 | 434.386 | 464.552 |
Total Common Shares Outstanding | 51.6927 | 51.5362 | 51.2565 | 45.3277 | 44.8794 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Netto-inkomen/Beginsaldo | -100.217 | -45.593 | -41.246 | -21.467 |
Geldmiddelen uit Operationele Activiteiten | -128.946 | 88.13 | 17.905 | -17.863 |
Geldmiddelen uit Operationele Activiteiten | 2.397 | 1.763 | 0.825 | 0.205 |
Niet-Geldelijke Posten | 30.797 | 7.093 | 1.639 | 1.091 |
Contant Betaalde Rente | 0.158 | 0.115 | 0.046 | 0.015 |
Veranderingen in het Operationeel Kapitaal | -61.923 | 124.867 | 56.687 | 2.308 |
Geldmiddelen uit Investeringsactiviteiten | -99.835 | -422.588 | -16.486 | -1.356 |
Kapitaaluitgaven | -1.597 | -9.096 | -0.532 | -1.356 |
Overige Cash Flow investeringsposten, Totaal | -98.238 | -413.492 | -15.954 | 0 |
Geldmiddelen uit Financieringsactiviteiten | 250.28 | 289.262 | 34.911 | 52.932 |
Uitgifte (Aflossing) van aandelen, netto | 249.18 | 276.289 | 35.282 | 53.227 |
Uitgifte (Aflossing) van Schulden, Netto | -0.849 | -0.554 | -0.371 | -0.295 |
Nettowijziging in Geldmiddelen | 21.499 | -45.196 | 36.33 | 33.713 |
Financiering van Cash Flow Posten | 1.949 | 13.527 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -36.684 | -100.217 | -66.317 | -37.735 | -13.075 |
Cash From Operating Activities | -40.295 | -128.946 | -90.594 | -53.334 | -22.823 |
Cash From Operating Activities | 0.687 | 2.397 | 1.708 | 1.037 | 0.485 |
Non-Cash Items | 9.048 | 30.797 | 20.483 | 11.409 | 4.451 |
Cash Interest Paid | 0.046 | 0.158 | 0.106 | 0.054 | 0.024 |
Changes in Working Capital | -13.346 | -61.923 | -46.468 | -28.045 | -14.684 |
Cash From Investing Activities | 25.863 | -99.835 | -31.816 | 105.046 | 44.323 |
Capital Expenditures | -0.482 | -1.597 | -1.096 | -0.79 | -0.164 |
Other Investing Cash Flow Items, Total | 26.345 | -98.238 | -30.72 | 105.836 | 44.487 |
Cash From Financing Activities | 0.185 | 250.28 | 248.226 | 2.187 | 0.595 |
Financing Cash Flow Items | 0 | 1.949 | 1.95 | -0.397 | -0.397 |
Issuance (Retirement) of Stock, Net | 0.449 | 249.18 | 246.969 | 2.925 | 1.147 |
Issuance (Retirement) of Debt, Net | -0.264 | -0.849 | -0.693 | -0.341 | -0.155 |
Net Change in Cash | -14.247 | 21.499 | 125.816 | 53.899 | 22.095 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
Atlas Venture | Venture Capital | 10.6159 | 5858262 | -126474 | 2023-01-12 | LOW |
BVF Partners L.P. | Hedge Fund | 8.5779 | 4733611 | 41007 | 2023-01-12 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 8.3197 | 4591089 | 1180703 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 7.8899 | 4353945 | 277562 | 2022-12-31 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 6.9767 | 3850000 | 1680770 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.619 | 3652608 | 797130 | 2022-12-31 | LOW |
Vertex Pharmaceuticals Inc | Corporation | 5.8007 | 3201049 | 49928 | 2022-03-31 | |
Baker Bros. Advisors LP | Hedge Fund | 5.2186 | 2879825 | 0 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.1577 | 2846221 | 160817 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.1454 | 2839421 | 172415 | 2022-12-31 | LOW |
Redmile Group, LLC | Investment Advisor/Hedge Fund | 4.8453 | 2673837 | -202800 | 2022-12-31 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 3.6243 | 2000000 | 500000 | 2022-12-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 3.5445 | 1955977 | -40552 | 2022-12-31 | MED |
Rock Springs Capital Management LP | Hedge Fund | 2.2249 | 1227779 | 181036 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.5331 | 846046 | 520360 | 2022-12-31 | LOW |
Wasatch Global Investors Inc | Investment Advisor/Hedge Fund | 1.5081 | 832221 | -228340 | 2022-12-31 | LOW |
EcoR1 Capital, LLC | Hedge Fund | 1.4426 | 796093 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3538 | 747071 | 45849 | 2022-12-31 | LOW |
Mellon Investments Corporation | Investment Advisor/Hedge Fund | 1.2316 | 679621 | -41254 | 2022-12-31 | LOW |
Aquilo Capital Management, LLC | Investment Advisor/Hedge Fund | 1.1406 | 629411 | 299165 | 2022-12-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Kymera Therapeutics, Inc. Company profile
Over Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is een biofarmaceutisch bedrijf. Het bedrijf richt zich op het ontdekken en ontwikkelen van kleine moleculegeneesmiddelen die selectief ziekteveroorzakende eiwitten afbreken door gebruik te maken van het lichaamseigen natuurlijke afbraaksysteem voor eiwitten. Haar Pegasus-platform (Targeted Protein Degradation) stelt haar in staat om selectieve kleine molecule-eiwitafbrekers te ontdekken met activiteit tegen ziekteveroorzakende eiwitten in het hele lichaam. Het Pegasus-platform van de Vennootschap omvat E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling, Quantitative System Pharmacology Model en Chemistry. De klinische programma's omvatten IRAK4, IRAKIMiD en STAT3, die zich elk richten op doelwitten binnen de interleukine-1 receptor/tol-achtige receptor (IL-1R/TLR), en janus kinase/signaaltransductoren en activatoren van transcriptie (JAK/STAT). De programma's zijn gericht op de behandeling van een reeks immuun-inflammatoire ziekten, hematologische maligniteiten en solide tumoren.
Industry: | Biotechnology & Medical Research (NEC) |
200 Arsenal Yards Blvd., Suite 230
2Nd Floor
02472
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen